| Literature DB >> 31038461 |
Rixt Zuidema1, Sandra van Dulmen2,3,4, Maria Nijhuis-van der Sanden1, Inger Meek5, Cornelia van den Ende6, Jaap Fransen5, Betsie van Gaal1,7.
Abstract
BACKGROUND: Web-based self-management enhancing programs have the potential to support patients with rheumatoid arthritis (RA) in their self-management; for example, improve their health status by increasing their self-efficacy or taking their prescribed medication. We developed a Web-based self-management enhancing program in collaboration with RA patients and professionals as co-designers on the basis of the intervention mapping framework. Although self-management programs are complex interventions, it is informative to perform an explorative randomized controlled trial (RCT) before embarking on a larger trial.Entities:
Keywords: arthritis, rheumatoid; internet; self-management
Mesh:
Year: 2019 PMID: 31038461 PMCID: PMC6658318 DOI: 10.2196/12463
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Overview of the 9 modules and their performance objectives.
| Module name | Performance objective: Patients need to... |
| Balancing activity and rest | ...find balance between rest and activity; make choices when participating in daily life activities to keep balance |
| Setting boundaries | ...set boundaries for their partner, relatives, colleagues and social environment |
| Asking for help and social support | ...ask for social support or practical help from their partner, relatives, colleagues and social environment in daily life; ask for social support and practical help from colleagues; accept receiving social support or practical help from their partner, relatives, colleagues and social environment in daily life |
| Use of medicines | ...take prescribed medication |
| Communication with health professionals | ...prepare for a visit to a health professional; ask questions and/or express concerns during an appointment with a health professional |
| Use of assistive devices | ...use, if necessary, assistive devices |
| Performing physical exercises | ...perform daily physical exercises |
| Coping with worries | ...cope with worries about RAa |
| Coping with RA | ...cope with RA |
aRA: rheumatoid arthritis.
Figure 1CONSORT flow diagram.
Demographics and disease-related characteristics at baseline.
| Characteristics | Control group | Intervention group | |||
| N | Statistics | N | Statistics | ||
| Age (years), mean (SD) | 62.9 (10.2) | 61.0 (11.3) | |||
| Men | 27 | 34 | 27 | 35 | |
| Women | 52 | 66 | 51 | 65 | |
| Disease duration, median (25th, 75th percentiles) | 79 | 17 (6.0, 26) | 77 | 9 (5.0, 19.5) | |
| Low | 28 | 35 | 10 | 13 | |
| Medium | 28 | 35 | 43 | 55 | |
| High | 23 | 29 | 25 | 32 | |
| Not working | 50 | 63 | 41 | 53 | |
| Part-time working | 7 | 9 | 7 | 9 | |
| Working | 22 | 28 | 30 | 39 | |
| Physical disability (M-HAQa), median (25th, 75th percentiles) | 79 | 0.5 (0.1, 1.4) | 78 | 0.6 (0.1, 1.1) | |
| NRS pain today, mean (SD) | 79 | 3.3 (2.3) | 77 | 3.2 (2.2) | |
| NRS mean pain last 2 weeks, mean (SD) | 79 | 3.9 (2.3) | 78 | 3.6 (2.3) | |
| NRS fatigue today (NRS), mean (SD) | 79 | 4.1 (2.5) | 78 | 3.8 (2.4) | |
| NRS mean fatigue last 2 weeks, mean (SD) | 79 | 4.3 (2.4) | 78 | 4.3 (2.3) | |
aM-HAQ: Modified Health Assessment Questionnaire.
Mean scores of outcome measurements on baseline, T1 and T2 of control and intervention groups.
| Scales, group | Baseline (T0) | T1 | T2 | ||||
| N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | ||
| Control | 57 | 46.9 (4.9) | 49 | 47.7 (4.8) | 45 | 47.8 (3.8) | |
| Intervention | 47 | 47.2 (3.7) | 35 | 46.7 (6.9) | 31 | 47.8 (2.9) | |
| Control | 79 | 36.0 (6.3) | 75 | 37.9 (6.8) | 74 | 37.6 (6.8) | |
| Intervention | 78 | 36.7 (7.1) | 57 | 39.4 (6.4) | 54 | 38.8 (7.0) | |
| Control | 79 | 99.4 (12.7) | 75 | 101.5 (10.6) | 74 | 99.9 (11.6) | |
| Intervention | 78 | 102.9 (10.2) | 57 | 101.9 (10.3) | 54 | 102.0 (7.4) | |
| Control | 79 | 21.6 (3.0) | 75 | 21.0 (3.2) | 73 | 20.6 (3.4) | |
| Intervention | 78 | 21.2 (3.3) | 57 | 21.3 (3.1) | 54 | 20.8 (3.1) | |
| Control | 78 | 58.1 (27.0) | 75 | 59.4 (26.5) | 74 | 61.8 (25.9) | |
| Intervention | 77 | 61.7 (26.1) | 57 | 65.9 (27.3) | 54 | 65.9 (26.7) | |
| Control | 79 | 73.3 (2476) | 75 | 72.7 (22.3) | 74 | 73.1 (22.4) | |
| Intervention | 78 | 71.3 (20.8) | 57 | 77.0 (19.6) | 54 | 70.8 (24.3) | |
| Control | 79 | 49.1 (43.6) | 75 | 51.11 (45.3) | 74 | 49.0 (43.1) | |
| Intervention | 78 | 49.0 (43.3) | 56 | 57.9 (42.0) | 54 | 49.1 (44.2) | |
| Control | 79 | 75.1 (40.5) | 73 | 84.9 (35.2) | 74 | 78.8 (39.2) | |
| Intervention | 77 | 80.1 (36.4) | 54 | 85.2 (31.5) | 54 | 78.4 (37.3) | |
| Control | 78 | 54.7 (14.3) | 75 | 72.6 (16.7) | 74 | 76.1 (14.6) | |
| Intervention | 78 | 52.6 (13.4) | 56 | 76.5 (12.0) | 54 | 75.9 (13.8) | |
| Control | 78 | 51.2 (22.7) | 75 | 53.9 (21.6) | 74 | 56.3 (21.2) | |
| Intervention | 78 | 53.1 (19.4) | 56 | 61.2 (15.1) | 54 | 62.5 (14.5) | |
| Control | 79 | 59.9 (21.3) | 75 | 60.8 (22.2) | 74 | 66.1 (21.8) | |
| Intervention | 78 | 64.3 (22.3) | 57 | 67.1 (21.0) | 54 | 63.9 (22.1) | |
| Control | 79 | 52.5 (18.7) | 75 | 47.8 (18.3) | 72 | 48.1 (17.5) | |
| Intervention | 77 | 52.7 (20.8) | 57 | 52.3 (19.5) | 48 | 50.4 (19.1) | |
| Control | 79 | 44.9 (21.2) | 75 | 50.3 (19.9) | 74 | 44.3 (19.7) | |
| Intervention | 78 | 47.8 (23.2) | 57 | 51.3 (20.8) | 54 | 43.5 (23.9) | |
| Control | 79 | 3.3 (2.3) | 75 | 3.2 (2.2) | 72 | 3.0 (2.2) | |
| Intervention | 77 | 3.2 (2.2) | 57 | 3.0 (2.3) | 48 | 3.3 (2.3) | |
| Control | 79 | 3.9 (2.3) | 75 | 3.8 (2.1) | 72 | 3.6 (2.2) | |
| Intervention | 78 | 3.6 (2.3) | 57 | 3.4 (2.3) | 48 | 3.9 (2.4) | |
| Control | 79 | 4.1 (2.5) | 75 | 3.8 (2.6) | 72 | 3.7 (2.3) | |
| Intervention | 78 | 3.8 (2.4) | 57 | 3.4 (2.4) | 48 | 3.6 (2.4) | |
| Control | 79 | 4.3 (2.4) | 75 | 4.2 (2.6) | 72 | 4.2 (2.4) | |
| Intervention | 78 | 4.3 (2.3) | 57 | 3.7 (2.1) | 48 | 4.0 (2.2) | |
| Control | 79 | 14.1 (4.8) | 75 | 14.1 (4.7) | 74 | 13.6 (4.3) | |
| Intervention | 78 | 14.1 (3.9) | 57 | 13.3 (3.3) | 54 | 13.6 (3.2) | |
aPAM: Patient Activation Measurement.
bSMAS-S: short Self-Management Ability Scale.
cRASE: Rheumatoid Arthritis Self-Efficacy.
dPEPPI-5: Perceived Efficacy in Patient-Physician Interaction.
eNRS: numerical rating scale.
fMPCI-F: Modified Pain Coping Inventory for Fatigue.
The estimated group differences between intervention and control groups after intention-to-treat analysis at 6 months and 12 months after baseline.
| Scales | 6 months after baseline | 12 months after baseline | ||||||
| T0-T1 change | 95% CI | Cohen | T0-T2 change | 95% CI | Cohen | |||
| PAMb (10-65) | –0.7 | –3.4 to 1.5 | .44 | 0.0 | –0.1 | –1.6 to 1.5 | .93 | 0.00 |
| SMAS-Sc (0-60) | 0.3 | –1.4 to 2.0 | .72 | 0.0 | 0.7 | –1.1 to 2.5 | .43 | 0.03 |
| RASEd (28-140) | –2.1 | –4.9 to 0.8 | .16 | 0.0 | 0.3 | –2.2 to 2.9 | .81 | 0.00 |
| PEPPI-5e (5-25) | 0.4 | –0.5 to 1.2 | .40 | 0.0 | 0.3 | –0.7 to 1.3 | .51 | 0.03 |
| RANDf physical functioning (0-100) | 2.5 | –3.3 to 8.1 | .40 | 0.00 | –0.2 | –5.4 to 5.1 | .96 | 0.00 |
| RAND social functioning (0-100) | 4.1 | –1.5 to 9.6 | .15 | 0.0 | –2.7 | –9.2 to 3.8 | .42 | –0.01 |
| RAND physical role limitations (0-100) | 5.6 | –7.0 to 18.2 | .38 | 0.00 | –2.8 | –14.9 to 9.3 | .65 | 0.00 |
| RAND emotional role limitations (0-100) | –3.2 | –14.1 to 7.6 | .56 | 0.00 | –3.9 | –16.0 to 8.3 | .53 | 0.00 |
| RAND mental health (0-100) | 2.8 | –1.1 to 6.8 | .16 | 0.0 | 0.9 | –3.0 to 4.7 | .66 | 0.00 |
| RAND vitality (0-100) | 3.4 | –1.5 to 8.3 | .17 | 0.0 | 5.4 | 0.2 to 10.7 | .04g | 0.01 |
| RAND pain (0-100) | 2.6 | –3.7 to 8.9 | .42 | 0.0 | –6.1 | –12.5 to 0.4 | .06 | –0.01 |
| RAND general health perception (0-100) | 2.2 | –2.2 to 6.7 | .33 | 0.0 | –0.1 | –4.5 to 4.4 | .98 | 0.00 |
| RAND health change (0-100) | 0.1 | –6.8 to 7.1 | .97 | 0.00 | –1.4 | –9.0 to 6.2 | .72 | 0.00 |
| NRSh pain today (0-10) | 0.0 | –0.6 to 0.7 | .97 | 0.00 | 0.5 | –0.1 to 1.2 | .13 | 0.10 |
| NRS mean pain last 2 weeks (0-10) | 0.0 | –0.7 to 0.6 | .97 | 0.00 | 0.7 | 0.0 to 1.4 | .60 | 1.13 |
| NRS fatigue today (0-10) | 0.2 | –0.5 to 0.8 | .66 | 0.0 | 0.3 | –0.4 to 0.9 | .46 | 0.01 |
| NRS mean fatigue last 2 weeks (0-10) | –0.23 | –0.9 to 0.4 | .45 | –0.1 | 0.1 | –0.6 to 0.7 | .81 | 0.00 |
| MPCI-Fi (4-32) | 0.1 | –0.8 to 0.9 | .90 | 0.00 | 0.3 | –0.7 to 1.2 | .58 | 0.01 |
aValues represent outcomes of the ITT analysis without confounders. After adding confounders, no changes in values appear.
bPAM: Patient Activation Measurement.
cSMAS-S: short Self-Management Ability Scale.
dRASE: Rheumatoid Arthritis Self-Efficacy.
ePEPPI-5: Perceived Efficacy in Patient-Physician Interaction.
fRAND-36: General Health Status.
gSignificant differences (P<.05) between control and intervention groups.
hNRS: numerical rating scale.
iMPCI-F: Modified Pain Coping Inventory for Fatigue.
Scores at baseline for the groups with a low and high usage of the intervention: demographic characteristics, disease-related characteristics, and outcome measures.
| Characteristics and outcome measures at baseline | Low usage | High usage | ||||
| N | Statistics | N | Statistics | |||
| Age (years), mean (SD) | 29 | 63.8 (10.5) | 40 | 58.9 (10.8) | .06 | |
| .55 | ||||||
| Men | 10 | 33 | 14 | 35 | ||
| Women | 20 | 67 | 26 | 65 | ||
| Disease duration | 29 | 8,0 (4,5, 22,5) | 40 | 8,5 (5,0, 18,7) | .80 | |
| .78 | ||||||
| Low | 3 | 10 | 5 | 13 | ||
| Middle | 19 | 63 | 22 | 55 | ||
| High | 8 | 28 | 13 | 33 | ||
| .28 | ||||||
| Not working | 22 | 73 | 23 | 58 | ||
| Working | 8 | 27 | 17 | 43 | ||
| Physical disability (Modified Health Assessment Questionnaire), (median [25th, 75th percentiles]) | 30 | 1.1 (0.2, 1.6)a | 40 | 0.5 (0.1, 1,0) | .03a | |
| PAMb (10-65), mean (SD) | 20 | 48.0 (3.3) | 20 | 46.2 (3.8) | .11 | |
| SMAS-Sc (0-60), mean (SD) | 30 | 36.5 (7.3) | 40 | 37.7 (7.0) | .48 | |
| RASEd (28-140), mean (SD) | 30 | 102.1 (10.9) | 40 | 103.4 (9.1) | .58 | |
| PEPPI-5e (5-25), mean (SD) | 30 | 21.5 (3.9) | 40 | 21.2 (2.8) | .68 | |
| RANDf physical functioning (0-100), mean (SD) | 29 | 54.3 (28.3) | 40 | 66.3 (24.6) | .07 | |
| RAND social functioning (0-100), mean (SD) | 30 | 64.6 (24.8) | 40 | 77.8 (17.1) | .02a | |
| RAND physical role limitations (0-100), mean (SD) | 30 | 36.7 (43.9) | 40 | 60.0 (42.7) | .03a | |
| RAND emotional role limitations (0-100), mean (SD) | 29 | 74.7 (41.5) | 40 | 85.8 (33.7) | .24 | |
| RAND mental health (0-100), mean (SD) | 30 | 72.1 (16.1) | 40 | 78.7 (11.6) | .06 | |
| RAND vitality (0-100), mean (SD) | 30 | 53.1 (22.9) | 40 | 61.7 (15.4) | .08 | |
| RAND pain (0-100), mean (SD) | 30 | 56.9 (25.5) | 40 | 69.8 (19.2) | .03a | |
| RAND general health perception (0-100), mean (SD) | 29 | 46.0 (19.4) | 40 | 54.0 (17.6) | .08 | |
| RAND health change (0-100), mean (SD) | 30 | 43.3 (20.7) | 40 | 52.5 (24.6) | .10 | |
| NRSg pain today (0-10), mean (SD) | 29 | 4.3 (2.5) | 40 | 2.5 (1.8) | .002a | |
| NRS mean pain last 2 weeks (0-10), mean (SD) | 30 | 4.4 (2.5) | 40 | 3.1 (2.1) | .02a | |
| NRS fatigue today (0-10), mean (SD) | 30 | 4.8 (2.4) | 40 | 3.0 (2.2) | <.001a | |
| NRS mean fatigue last 2 weeks (0-10), mean (SD) | 30 | 4.8 (2.4) | 40 | 3.0 (2.2) | <.001a | |
| MPCI-Fh (4-32), mean (SD) | 30 | 15.0 (4.8) | 40 | 13.2 (3.0) | .08 | |
aSignificant differences (P<.05) between the group low and high users.
bPAM: Patient Activation Measurement.
cSMAS-S: short Self-Management Ability Scale.
dRASE: Rheumatoid Arthritis Self-Efficacy.
ePEPPI-5: Perceived Efficacy in Patient-Physician Interaction.
fRAND-36: General Health Status.
gNRS pain/fatigue: Numeric Rating scales pain/fatigue.
hCoping with fatigue: Modified Pain Coping Inventory for Fatigue.
The estimated difference between the group with low and high usage of the intervention after sensitivity analysis at 6 months and 12 months after baseline.
| Scales | 6 months after baseline | 12 months after baseline | ||||||
| T0-T1 change | 95% CI | Cohen | T0-T2 change | 95% CI | Cohen | |||
| PAMb (10-65) | 2.4 | –1.7 to 6.4 | .24 | 0.12 | 0.0 | –2.9 to 2.9 | >.99 | 0.00 |
| SMAS-Sc (0-60) | –0.4 | –3.4 to 2.7 | .82 | 0.00 | 1.3 | –2.0 to 4.5 | .44 | 0.02 |
| RASEd (28-140) | –1.7 | –6.8 to 3.4 | .52 | –0.00 | –0.6 | –5.3 to 4.1 | .81 | 0.00 |
| PEPPI-5e (5-25) | –1.0 | –2.5 to 0.5 | .20 | –0.11 | –0.1 | –1.9 to 1.7 | .93 | 0.00 |
| RANDf physical functioning (0-100) | 9.2 | –0.7 to 19.2 | .07 | 0.01 | 2.2 | –7.4 to 11.8 | .65 | 0.00 |
| RAND social functioning (0-100) | 1.5 | –8.4 to 11.4 | .76 | 0.00 | 5.3 | –6.7 to 17.4 | .38 | 0.01 |
| RAND physical role limitations (0-100) | 7.4 | –14.7 to 29.5 | .51 | 0.00 | 3.7 | –18.6 to 25.9 | .74 | 0.00 |
| RAND emotional role limitations (0-100) | 16.1 | –3.6 to 35.7 | .11 | 0.01 | –1.7 | –24.5 to 21.0 | .88 | 0.00 |
| RAND mental health (0-100) | 0.8 | –6.3 to 7.9 | .83 | 0.00 | –4.2 | –11.2 to 2.8 | .24 | –0.02 |
| RAND vitality (0-100) | 2.9 | –5.6 to 11.5 | .50 | 0.01 | –1.2 | –10.8 to 8.4 | .81 | 0.00 |
| RAND pain (0-100) | 1.7 | –4.5 to 12.9 | .77 | 0.00 | 8.8 | –3.0 to 20.6 | .14 | 0.02 |
| RAND general health perception (0-100) | 2.9 | –5.1 to 10.8 | .48 | 0.01 | 9.7 | 0.8 to 18.5 | .03g | 0.02 |
| RAND health change (0-100) | 8.3 | –4.0 to 20.5 | .19 | 0.02 | 6.4 | –7.9 to 20.6 | .38 | 0.01 |
| NRSh pain today (0-10) | 0.0 | –1.2 to 1.2 | >.99 | 0.00 | –0.6 | –1.9 to 0.8 | .41 | –0.11 |
| NRS mean pain last 2 weeks (0-10) | –0.6 | –1.8 to 0.5 | .29 | –0.12 | 0.9 | –2.3 to 0.6 | .24 | –0.16 |
| NRS fatigue today (0-10) | 0.2 | –1.0 to 1.3 | .73 | 0.03 | –0.9 | –2.2 to 0.5 | .22 | –0.14 |
| NRS mean fatigue last 2 weeks (0-10) | 0.2 | –1.0 to 1.3 | .78 | 0.03 | –0.5 | –1.7 to 0.8 | .51 | –0.08 |
| MPCI-Fi (4-32) | –0.2 | –1.7 to 1.3 | .76 | –0.01 | –0.4 | –2.1 to 1.3 | .67 | –0.01 |
aValues represent outcomes of the ITT analysis without confounders. After adding confounders, no changes in values appear.
bPAM: Patient Activation Measurement.
cSMAS-S: short Self-Management Ability Scale.
dRASE: Rheumatoid Arthritis Self-Efficacy.
ePEPPI-5: Perceived Efficacy in Patient-Physician Interaction.
fRAND-36: General Health Status.
gSignificant differences (P<.05) between control and intervention groups.
hNRS: numerical rating scale.
iMPCI-F: Modified Pain Coping Inventory for Fatigue.